"Business Segments:
Viatris reports segment information on the basis of markets and geography. In conjunction with the formation of Viatris, the Company has
changed its reportable segments, from North America, Europe, and Rest of World, to Developed Markets, Greater China, JANZ, and Emerging Markets.
This approach reflects the Company’s focus on bringing its broad and diversified portfolio of branded, complex generics, and generic products to people in
markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment
includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging
Markets segment encompasses our operations in countries with developing markets and emerging economies including countries in Asia, the Middle East,
South and Central America, Africa and Eastern Europe, and also includes the Company’s ARV franchise."
In 2025, Viatris reported billion U.S. dollars in net sales. Of that amount, ***Â billion dollars were generated through branded products. Viatris is a global healthcare company headquartered in the United States, with centers in Pennsylvania, Shanghai, and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆÆ½â°æ can support your business.
Viatris, & U.S. Securities and Exchange Commission. (February 26, 2026). Net sales of Viatris from 2022 to 2025, by business segments (in million U.S. dollars) [Graph]. In ÌÇÐÄÆÆ½â°æ. Retrieved July 23, 2026, from /statistics/1234956/net-sales-business-segment-viatris/
Viatris, und U.S. Securities and Exchange Commission. "Net sales of Viatris from 2022 to 2025, by business segments (in million U.S. dollars) ." Chart. February 26, 2026. ÌÇÐÄÆÆ½â°æ. Accessed July 23, 2026. /statistics/1234956/net-sales-business-segment-viatris/
Viatris, U.S. Securities and Exchange Commission. (2026). Net sales of Viatris from 2022 to 2025, by business segments (in million U.S. dollars) . ÌÇÐÄÆÆ½â°æ. ÌÇÐÄÆÆ½â°æ Inc.. Accessed: July 23, 2026. /statistics/1234956/net-sales-business-segment-viatris/
Viatris, and U.S. Securities and Exchange Commission. "Net Sales of Viatris from 2022 to 2025, by Business Segments (in Million U.S. Dollars) ." ÌÇÐÄÆÆ½â°æ, ÌÇÐÄÆÆ½â°æ Inc., 26 Feb 2026, /statistics/1234956/net-sales-business-segment-viatris/
Viatris & U.S. Securities and Exchange Commission, Net sales of Viatris from 2022 to 2025, by business segments (in million U.S. dollars) ÌÇÐÄÆÆ½â°æ, /statistics/1234956/net-sales-business-segment-viatris/ (last visited July 23, 2026)
Net sales of Viatris from 2022 to 2025, by business segments (in million U.S. dollars) [Graph], Viatris, & U.S. Securities and Exchange Commission, February 26, 2026. [Online]. Available: /statistics/1234956/net-sales-business-segment-viatris/